Trial Profile

Phase 2 Study of Anlotinib With PD-1 Inhibitor as Second Line Therapy in the Treatment of Metastatic Pancreatic Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Carcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use

Most Recent Events

23 Feb 2022 Drug pembrolizumab added newly for class PD-1 inhibitor. Maximum age of patient reported as 80 Years.
06 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com